Connection

Martine Bagot to Receptors, KIR3DL2

Back to Details
This is a "connection" page, showing publications Martine Bagot has written about Receptors, KIR3DL2.
Martine Bagot
Connection Strength
1.890
Receptors, KIR3DL2
  1. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncol. 2019 08; 20(8):1160-1170.
    View in: PubMed
    Score: 0.822
  2. IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma. Expert Opin Investig Drugs. 2018 Aug; 27(8):691-697.
    View in: PubMed
    Score: 0.192
  3. KIR3DL2 expression in patients with adult T-cell lymphoma/leukaemia. Br J Dermatol. 2018 07; 179(1):197-199.
    View in: PubMed
    Score: 0.190
  4. KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting. Blood. 2017 12 28; 130(26):2900-2902.
    View in: PubMed
    Score: 0.183
  5. Circulating and skin-derived Sézary cells: clonal but with phenotypic plasticity. Blood. 2017 09 21; 130(12):1468-1471.
    View in: PubMed
    Score: 0.180
  6. Usefulness of KIR3DL2 to Diagnose, Follow-Up, and Manage the Treatment of Patients with Sézary Syndrome. Clin Cancer Res. 2017 Jul 15; 23(14):3619-3627.
    View in: PubMed
    Score: 0.174
  7. IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma. Cancer Res. 2014 Nov 01; 74(21):6060-70.
    View in: PubMed
    Score: 0.149
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.